Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy

Author(s): Xiao-Na Fang, Li-Wu Fu

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 11 , Issue 2 , 2016

Become EABM
Become Reviewer
Call for Editor


Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could benefit from anti-PD-1/PD-L1 therapy, while others still worsened. The key to this point is that there are no efficient biomarkers for screening anti-PD-1/PD-L1-sensitive patients. In this review, we aim at summarizing the latest advances of anti-PD-1/PDL1 immunotherapy and the potential predictive efficacy biomarkers to provide evidences for identifying anti-PD-1/PDL1- sensitive patients. The present article also includes the patent review coverage on this topic.

Keywords: Efficacy, immune check-point, immunotherapy, monoclonal antibodies, predictive efficacy biomarkers, programmed cell death 1, programmed cell death 1 ligand.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 15 April, 2016
Page: [141 - 151]
Pages: 11
DOI: 10.2174/1574892811666160226150506
Price: $65

Article Metrics

PDF: 102
PRC: 1